Abstract
The search for new treatments of asthma and related airway disorders is a continuing quest of pulmonologists, pharmacologists, and pharmaceutical industries documented from as early as 1600 BC (1). The approach of modern medicine has been to identify key procontractile compounds and mediators with the hope of obtaining antagonists to a major clinical outcome, namely the loss of respiratory volume (2). New approaches are needed because many of the current treatments (e.g., antileukotriene drugs, antihistamines, and steroids) are only effective in a portion of those afflicted with asthma and the side effects of these treatments have proved to be a formidable challenge (3, 4). More recently, it has been appreciated that inflammation plays a critical role in asthma, particularly the recruitment of specialized leukocytes, neutrophils, eosinophils, and lymphocytes to lung, and eventually to airways (5). Hence, one strategy may involve the identification of novel antiinflammatory agents that could dampen the clinical sequelae in various forms of asthma. It is in this context that we consider this perspective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of respiratory cell and molecular biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
